Abemaciclib is a CDK4/6 inhibitor which has now been approved for HR+ HER2 – node positive high-risk early breast cancer
Eli Lilly and Company (India) has launched the additional indication for Ramiven (abemaciclib), following approval from The Drug Controller General of India (DCGI) in combination with endocrine therapy for adjuvant treatment in adult patients with hormone receptor (HR)positive, human epidermal growth factor receptor 2(HER2) negative, node-positive early breast cancer (EBC) at high risk of recurrence.
CDK 4/6 inhibitors are a class of medicines used to treat certain types of metastatic breast cancers.
Vineet Gupta, Managing Director, Eli Lilly and Company – India & India Subcontinent, said, “Breast cancer is cancer which is most prevalent amongst women in India. It significantly impacts the quality of life of survivors and their families, who live with the fear of recurrence. The approval of Ramiven for treatment of Early Breast Cancer brings more optimism by providing a new treatment option to the healthcare professionals for their patients.”
Ramiven is already approved for the treatment of certain types of HR+ HER2- advanced or metastatic breast cancer.
Ramiven is a prescription drug to be used only on the advice of an oncologist and under medical supervision. It is available in tablet strengths of 150 mg, 100 mg, and 50 mg for EBC.
